Russell Investments Group
KPTI icon

Russell Investments Group’s Karyopharm Therapeutics KPTI Stock Holding History

Russell Investments Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-435
Closed -$5.64K – 3345
2023
Q4 		$5.64K Sell
435
-5,889
-93% -$79.4K ﹤0.01% 2896
2023
Q3 		$127K Sell
6,324
-40
-0.6% -$898 ﹤0.01% 2581
2023
Q2 		$171K Buy
6,364
+72
+1% +$3.1K ﹤0.01% 2503
2023
Q1 		$367K Sell
6,292
-3,452
-35% -$170K ﹤0.01% 2351
2022
Q4 		$497K Buy
9,744
+1,116
+13% +$77.4K ﹤0.01% 2289
2022
Q3 		$705K Buy
8,628
+1,355
+19% +$101K ﹤0.01% 2093
2022
Q2 		$491K Buy
7,273
+3,223
+80% +$296K ﹤0.01% 2278
2022
Q1 		$447K Buy
4,050
+4,003
+8,517% +$499K ﹤0.01% 2264
2021
Q4 		$4K Sell
47
-120
-72% -$12K ﹤0.01% 2984
2021
Q3 		$14K Sell
167
-3,344
-95% -$347K ﹤0.01% 3006
2021
Q2 		$542K Buy
3,511
+616
+21% +$89.4K ﹤0.01% 2565
2021
Q1 		$456K Sell
2,895
-834
-22% -$176K ﹤0.01% 2561
2020
Q4 		$864K Sell
3,729
-378
-9% -$87.6K ﹤0.01% 2179
2020
Q3 		$898K Buy
4,107
+2,190
+114% +$536K ﹤0.01% 2122
2020
Q2 		$543K Buy
+1,917
New +$567K ﹤0.01% 2355
2020
Q1 		– Sell
-1,107
Closed -$318K – 3089
2019
Q4 		$318K Buy
+1,107
New +$240K ﹤0.01% 2560
2018
Q3 		– Sell
-293
Closed -$75K – 2984
2018
Q2 		$75K Sell
293
-27
-8% -$6.68K ﹤0.01% 2768
2018
Q1 		$64K Hold
320
– – ﹤0.01% 2800
2017
Q4 		$47K Buy
+320
New +$51.4K ﹤0.01% 2873
2017
Q2 		– Sell
-4,992
Closed -$962K – 3000
2017
Q1 		$962K Buy
4,992
+2,544
+104% +$408K ﹤0.01% 2117
2016
Q4 		$343K Buy
+2,448
New +$331K ﹤0.01% 2579

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Investments Group's KPTI Position: Q1 2024 in Review

Russell Investments Group sold out of Karyopharm Therapeutics (KPTI) in Q1 2024, closing a stake of 435 shares — an estimated $5.64K sold.

Russell Investments Group first reported a position in KPTI in Q4 2016 and held it in 21 quarters. The position peaked at $962K in Q1 2017. 113 funds tracked by Wall St. Rank hold KPTI as of Q1 2024.

  • Russell Investments Group reported no remaining Karyopharm Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Russell Investments Group sold 435 Karyopharm Therapeutics shares in Q1 2024, an estimated $5.64K.
  • Russell Investments Group first reported a position in Karyopharm Therapeutics in Q4 2016 and held it in 21 quarters.
  • Russell Investments Group's Karyopharm Therapeutics position peaked at $962K in Q1 2017.
  • 113 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2024.

Based on Russell Investments Group's 13F filing for Q1 2024, filed 8 May 2024.